Tibotec said that it has collaborated with Emcure because of the company’s strong reputation in India and extensive reach through its country-wide distribution network. The agreement will help to build a sustainable effort in India to ensure patients in need have access to darunavir.
Tibotec has been working with regulatory authorities in India to register darunavir. When approved, darunavir, co-administered with ritonavir and with other antiretroviral agents, is expected to be indicated for the treatment of human immunodeficiency virus infection in antiretroviral treatment experienced adult patients.
Wlodek Kubiak, vice president of worldwide access programs at Tibotec, said: “Tibotec believes that strong collaborations with companies such as Emcure provide the best options for HIV/AIDS patients by enhancing drug access and maintaining the quality of medicines.”